Navigation Links
Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
Date:4/16/2008

VALENCIA, Calif., April 16 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced that Matthew J. Pfeffer will join the company as Corporate Vice President and Chief Financial Officer, effective April 21, 2008. Mr. Pfeffer will report to Hakan Edstrom, President and Chief Operating Officer, and will serve on MannKind's executive leadership team. Mr. Pfeffer's appointment follows the previously announced retirement of Dick Anderson, who has now transitioned to the role of Corporate Vice President -- Office of the Chairman.

Mr. Pfeffer served as Chief Financial Officer and Senior Vice President of Finance and Administration of VaxGen, Inc. from March 2006 until April 2008, with responsibility for finance, tax, treasury, human resources, IT, purchasing and facilities functions. Prior to VaxGen, Mr. Pfeffer served as CFO of Cell Genesys, Inc. During his nine-year tenure at Cell Genesys, Mr. Pfeffer served as Director of Finance before being named CFO in 1998. Prior to that, Mr. Pfeffer served in a variety of financial management positions at other companies, including roles as Corporate Controller, Manager of Internal Audit and Manager of Financial Reporting. Mr. Pfeffer began his career at Price Waterhouse. Mr. Pfeffer is a member of the board of directors of Genelabs Technologies, Inc. He also serves on boards and advisory committees of Financial Executives International, the Biotechnology Industry Organization and the American Institute of Certified Public Accountants. Mr. Pfeffer graduated from the University of California, Berkeley and is a Certified Public Accountant.

"Matt is a seasoned and knowledgeable Chief Financial Officer with over 25 years of demonstrated financial management experience. We know that he will play a significant role on MannKind's executive leadership team as we continue to develop our pipeline of diabetes and oncology products," said Hakan Edstrom. "We are extremely pleased to have him on the team."

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
2. Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales
3. Cord Blood America CEO Matthew Schissler Interviewed by BIONOVA, Greeces Leading Biotech Magazine
4. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
5. Genstructs Andrea Matthews Selected for Mass High Techs People to Watch Under 30
6. The Scripps Translational Science Institute Joins The MetaMiner Cardiac Consortium
7. Cord Blood America Says Pennsylvania Joins New York and California in Establishing Educational Programs on the Benefits of Umbilical Cord Blood Storage
8. Holly Smith Joins Profect as Director of Clinical Imaging Services
9. Ex-Allergan Vice President Joins Kalologie Skincare Board of Directors
10. Dr. Linda McAllister Joins Arbor Vita Corporation as Vice President of Diagnostics
11. Louis Drapeau Joins Bionovos Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 2016  Allergan plc (NYSE: AGN ) a ... Saunders , Allergan,s CEO and President, will be featured ... at the RBC Capital Markets Healthcare Conference on Tuesday, ... New York Palace Hotel in New York, ... and can be accessed on Allergan,s Investor Relations web ...
(Date:2/10/2016)... Latham, NY (PRWEB) , ... February 10, 2016 , ... ... photodiode packages at the SPIE Photonics West conference in San Francisco’s Moscone ... and 14 in the same venue. , These latest InGaAs PIN diode standard ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... a new agreement with Singapore-based Global Stem Cells Network (GSCN) and its affiliate ... and Singapore in the latest adipose and bone marrow therapies. , Through ...
(Date:2/9/2016)... 2016  Regenicin, Inc. (OTC Bulletin Board: ... development and commercialization of regenerative cell therapies to ... recently reported the Company,s operating results for 2015 ... Lonza America , Inc. (the "Lonza ... in the process of consummating an agreement to ...
Breaking Biology Technology:
(Date:2/9/2016)... Feb. 9, 2016 Vigilant Solutions announces today that ... (LPR) to develop a lead in a difficult homicide case. ... data to locate the suspect vehicle. Due to the ongoing ... have been omitted at the agency,s request. ... explains, "Our victim was found deceased at an intersection here ...
(Date:2/4/2016)... -- The field of Human Microbiome research and ... hubs of the biotechnology industry. While the Human ... human microbiota, have garnered a lot of attention ... has literally exploded in terms of both basic ... on biomedical aspects of research, development, and commercial ...
(Date:2/3/2016)... Feb. 3, 2016 Vigilant Solutions announces today ... in Missouri solved two recent ... (LPR) data from Vigilant Solutions. Brian Wenberg ... which the victim was walking out of a convenience store and witnessed an ... to his vehicle, striking his vehicle and leaving the ...
Breaking Biology News(10 mins):